USFDA grants Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis therapy
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
Subscribe To Our Newsletter & Stay Updated